U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22FN3O2
Molecular Weight 379.4274
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROPERIDOL

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4

InChI

InChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula C22H22FN3O2
Molecular Weight 379.4274
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.

CNS Activity

Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
INAPSINE

Approved Use

Droperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.

Launch Date

1970
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26.6 μg/L
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.5 μg/L
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
40 μg × h/L
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.7 μg × h/L
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.1 h
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.4 h
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.4 mg/kg multiple, oral
unhealthy, 2-9 years
Disc. AE: QT interval prolonged...
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Other AEs: Asthenia, Chills...
Other AEs:
Asthenia (24.6%)
Chills (3.3%)
Anorexia (3.3%)
Akathisia (16.4%)
Anxiety (27.9%)
Confusion (3.3%)
Dizziness (9.8%)
Dry mouth (9.8%)
Nervousness (4.9%)
Paresthesia (3.3%)
Somnolence (24.6%)
Tremor (1.6%)
Pharyngitis (4.9%)
Rhinitis (4.9%)
Sweaty (8.2%)
Sources:
2.5 mg multiple, intravenous
unhealthy
Disc. AE: Torsades de pointes...
AEs

AEs

AESignificanceDosePopulation
QT interval prolonged Disc. AE
0.4 mg/kg multiple, oral
unhealthy, 2-9 years
Tremor 1.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Akathisia 16.4%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Asthenia 24.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Somnolence 24.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Anxiety 27.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Anorexia 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Chills 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Confusion 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Paresthesia 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Nervousness 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Pharyngitis 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Rhinitis 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Sweaty 8.2%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Dizziness 9.8%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Dry mouth 9.8%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
Health Status: unhealthy
Age Group: 42 ± 10.0 years
Sex: M+F
Sources:
Torsades de pointes Disc. AE
2.5 mg multiple, intravenous
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients.
2001 Apr-Jun
[Intraoperative memory. A study of its incidence in general anesthesia in 326 patients].
2001 Aug
Variation in practice patterns of anesthesiologists in California for prophylaxis of postoperative nausea and vomiting.
2001 Aug
Effects of dopamine antagonists in human eye accommodation.
2001 Feb
Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review.
2001 Feb
Prevention of postoperative nausea and vomiting with antiemetics in patients undergoing middle ear surgery: comparison of a small dose of propofol with droperidol or metoclopramide.
2001 Jan
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
2001 Jul
Pediatric renal transplantation: anesthesia and perioperative complications.
2001 Mar
[Droperidol and dimenhydrinate alone or in combination for prevention of postoperative nausea and vomiting].
2001 May
Impact of antiemetic selection on postoperative nausea and vomiting and patient satisfaction.
2001 May
[Postoperative nausea--still a problem].
2001 Oct 3
[Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy].
2002 Jan
[Droperidol causes multifocal ventricular dysrhythmias].
2002 Jan
Premedication, preparation, and surveillance.
2002 Jan
The FDA droperidol warning: is it justified?
2002 Jul
Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure.
2002 Jun
Gateways to Clinical Trials. June 2002.
2002 Jun
Treatment patterns of isolated benign headache in US emergency departments.
2002 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous or Intramuscular
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely. Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration: Intravenous
Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:55:21 GMT 2025
Edited
by admin
on Wed Apr 02 07:55:21 GMT 2025
Record UNII
O9U0F09D5X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DROPERIDOL
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
DROLEPTAN
Preferred Name English
R-4749
Code English
NSC-169874
Code English
DROPERIDOL [VANDF]
Common Name English
DROPERIDOL [ORANGE BOOK]
Common Name English
MCN-JR-4749
Code English
DROPERIDOL [GREEN BOOK]
Common Name English
DROPERIDOL [USP-RS]
Common Name English
INNOVAR COMPONENT DROPERIDOL
Common Name English
DROPERIDOL [MART.]
Common Name English
DROPERIDOL [USP MONOGRAPH]
Common Name English
Droperidol [WHO-DD]
Common Name English
1-(1-(3-(P-FLUOROBENZOYL)PROPYL)-1,2,3,6-TETRAHYDRO-4-PYRIDYL)-2-BENZIMIDAZOLINONE
Common Name English
DROPERIDOL [HSDB]
Common Name English
DROPERIDOL [USAN]
Common Name English
DROPERIDOL [JAN]
Common Name English
2H-BENZIMIDAZOL-2-ONE, 1-(1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1,3-DIHYDRO-
Systematic Name English
droperidol [INN]
Common Name English
DROPERIDOL [MI]
Common Name English
INAPSINE
Brand Name English
DROPERIDOL [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AD08
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
CFR 21 CFR 522.800
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
LIVERTOX 332
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
NCI_THESAURUS C323
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
NDF-RT N0000175800
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
NDF-RT N0000175799
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
WHO-VATC QN05AD08
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
WHO-ATC N01AX01
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
Code System Code Type Description
MESH
D004329
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
DRUG CENTRAL
966
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
CHEBI
4717
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
DRUG BANK
DB00450
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
CAS
548-73-2
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-957-8
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
NCI_THESAURUS
C458
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
RS_ITEM_NUM
1229001
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
WIKIPEDIA
Droperidol
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
LACTMED
Droperidol
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
EVMPD
SUB06410MIG
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
HSDB
3320
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
RXCUI
3648
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m4769
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY Merck Index
FDA UNII
O9U0F09D5X
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
NSC
169874
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
IUPHAR
7172
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL1108
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
INN
1609
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID6022973
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
SMS_ID
100000081007
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
PUBCHEM
3168
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
DAILYMED
O9U0F09D5X
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC